Clinical Trial: Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778290) titled 'Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer' on Aug. 18.

Brief Summary: This study evaluates a topical 2% Boswellia serrata (Indian olibanum) gum-resin cream for the prevention of acute radiation-induced dermatitis in patients with head and neck cancer undergoing radiotherapy. Participants in the intervention group apply the cream to the radiation field twice daily throughout the radiotherapy course; the control group receives no preventive topical treatment (rescue treatment only if skin reactions occur). The two co-primary outcomes are the proportion of patients who require rescue treatment...